Royalty Pharma PLC $RPRX Shares Newly Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 153,549 shares of the biopharmaceutical company’s stock, valued at approximately $8,961,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. CoreCap Advisors LLC grew its holdings in Royalty Pharma by 89.2% in the 2nd quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 413 shares in the last quarter. Root Financial Partners LLC purchased a new position in shares of Royalty Pharma during the third quarter worth about $62,000. Bessemer Group Inc. raised its holdings in Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 282 shares in the last quarter. IFP Advisors Inc lifted its holdings in Royalty Pharma by 263.3% in the second quarter. IFP Advisors Inc now owns 1,188 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 861 shares during the period. Finally, Oslo Pensjonsforsikring AS acquired a new stake in shares of Royalty Pharma during the 1st quarter valued at approximately $95,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. The Goldman Sachs Group reissued a “buy” rating and set a $66.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. Bank of America restated a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. TD Cowen increased their target price on Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. JPMorgan Chase & Co. raised their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, September 14th. Eight investment analysts have rated the stock with a Buy rating. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $61.57.

Insider Buying and Selling

In other news, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the sale, the executive vice president owned 270,401 shares in the company, valued at $15,826,570.53. The trade was a 27.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 208,252 shares of company stock worth $12,324,407 in the last quarter. Insiders own 18.84% of the company’s stock.

Royalty Pharma Price Performance

RPRX opened at $67.56 on Thursday. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a 52-week low of $36.03 and a 52-week high of $67.71. The company has a 50 day moving average of $60.59 and a two-hundred day moving average of $53.53. The company has a market cap of $38.85 billion, a P/E ratio of 46.59, a P/E/G ratio of 1.82 and a beta of 0.37.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.27 by $0.05. The company had revenue of $674.14 million for the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. On average, analysts expect that Royalty Pharma PLC will post 5.29 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is 64.83%.

Key Stories Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Royalty Pharma raised its FY2026 royalty-receipts outlook to $3.55 billion, alongside reported quarterly growth. The stronger outlook is a key positive signal for expected royalty cash flows. Article: Royalty Pharma Q3 Results Show Growth; Raises FY26 Receipts Outlook
• Positive Sentiment: Zacks reported adjusted Q3 earnings of $1.21 per share, above its $1.18 consensus estimate and up from $1.17 a year earlier. Article: Royalty Pharma Q3 Earnings and Revenues Surpass Estimates
• Neutral Sentiment: A Seeking Alpha analysis characterized Royalty Pharma’s royalty-acquisition model as diversified and defensive, with exposure to established biopharmaceutical therapies. This is a longer-term investment perspective rather than a new company announcement. Article: Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play
• Negative Sentiment: Reported GAAP EPS was $0.32, versus the $1.18 consensus cited in the provided results, while revenue of $690.1 million was below the cited $884.8 million estimate. The contrast with the adjusted-earnings beat reflects differing earnings measures and estimates, but the reported shortfall is a potential concern. Article: Royalty Pharma Q3 earnings results

Royalty Pharma Company Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.